Spectrum CannaLabs protects the health and safety of the world’s 260 million active cannabis users with breakthrough testing protocols based on nearly two decades of experience in biotech and clinical trials for the pharmaceutical industry.
San Francisco-based Spectrum CannaLabs are the pioneers of breakthrough testing protocol for the $344 Billion global cannabis industry, which encompasses 260 million active users.
Spectrum CannaLabs is the first and only company to provide a pharmaceutical-grade testing solution for the scientific development of new cannabis-based treatments for disease, chronic illness and a new generation of cannabis wellness solutions.
CEO Carlos Balagot is a plant biotechnologist who previously conducted clinical trials for AstraZeneca, one of the world’s largest pharmaceutical companies, and pioneer in biopharmacology. Spectrum’s founding team brings more than 40 years of experience and relationships from the pharmaceutical industry, healthcare, consumer packaged goods and logistics.
Spectrum CannaLabs is the exclusive cannabis research partner for Agilent Scientific Instruments, makers of the world’s most advanced cannabis testing equipment.